411 related articles for article (PubMed ID: 29284356)
1. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
2. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T; Yoshimoto G; Kamimura T; Muta T; Takashima S; Ito Y; Shiratsuchi M; Choi I; Kato K; Takenaka K; Iwasaki H; Takamatsu Y; Teshima T; Akashi K
Int J Hematol; 2013 Sep; 98(3):337-45. PubMed ID: 23877150
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M;
Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643
[TBL] [Abstract][Full Text] [Related]
5. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
6. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
8. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
9. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.
Martino M; Olivieri A; Offidani M; Vigna E; Moscato T; Fedele R; Montanari M; Console G; Gentile M; Messina G; Irrera G; Morabito F
Expert Opin Investig Drugs; 2013 May; 22(5):619-34. PubMed ID: 23550793
[TBL] [Abstract][Full Text] [Related]
10. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
[TBL] [Abstract][Full Text] [Related]
11. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Imataki O; Aoyama T; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Doo NW; Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Joyce T; Harrison SJ
Leuk Lymphoma; 2013 Jul; 54(7):1465-72. PubMed ID: 23121086
[TBL] [Abstract][Full Text] [Related]
18. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
19. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
Mark TM; Reid W; Niesvizky R; Gergis U; Pearse R; Mayer S; Greenberg J; Coleman M; Van Besien K; Shore T
Biol Blood Marrow Transplant; 2013 May; 19(5):831-7. PubMed ID: 23454184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
